Companies › GIE Medical
1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GIE Medical ProTractX3 TTS DCB Paclitaxel-coated balloon catheter | Tubulin | Phase 3 | Bowel; Stricture; Esophageal Stricture | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05561127 | GIE Medical ProTractX3 TTS DCB | Phase 3 | Bowel; Stricture | Gastroenterology | Dec 2027 |
| NCT05561114 | GIE Medical ProTractX3 TTS DCB | Phase 3 | Esophageal Stricture | Gastroenterology | Apr 2031 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic
Ostia Sciences Cook MyoSite Myungmoon Pharma. Pharmicell Green Cross Wellbeing
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.